Piscataway, NJ, November 17, 2022–Camber Pharmaceuticals is pleased to announce the addition of Lamotrigine ER Tablets to its current portfolio.
Lamotrigine ER Tablets are indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial- onset seizures with or without secondary generalization in patients aged 13 years and older.
Lamotrigine ER Tablets from Camber are available in 25, 50, 100, 200, 250, and 300 mg strengths in 30 count bottles.
To find out more about Lamotrigine ER Tablets please visit www.camberpharma.com
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
# # #
If you would like more information about this topic, please contact Megan Little at [email protected]